A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer

Trial Profile

A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 23 May 2017

At a glance

  • Drugs Panobinostat (Primary)
  • Indications Head and neck cancer; Oesophageal cancer; Prostate cancer
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 25 Jan 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Jan 2011 Actual end date (January 2010) added as reported by ClinicalTrials.gov.
    • 14 Oct 2008 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top